Oncopeptides strengthens its organization by appointing Karolina Vilval as General Counsel

STOCKHOLM — March 2, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Karolina Vilval has been appointed as General Counsel of Oncopeptides. Karolina has 15 years of experience from different positions at Swedish Orphan Biovitrum. Prior to joining Oncopeptides, she served as Associate Legal Director at Gilead Sciences Sweden AB for business area Oncology, HIV and Inflammation. She will be a member Oncopeptides’ Management Team and will start today.

For more information, please contact:
Jakob Lindberg, CEO of Oncopeptides
E-mail: 
jakob.lindberg@oncopeptides.com  
Telephone: +46 8 615 20 40

 

Rein Piir, Head of Investor Relations at Oncopeptides
E-mail: 
rein.piir@oncopeptides.com  
Cell phone: +46 70 853 72 92


This information was submitted for publication at 08.00 CET March 2, 2020.

About Oncopeptides
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being tested in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides’ headquarters is in Stockholm, Sweden, and the company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.

More information is available on www.oncopeptides.com.

Tags:

About Us

Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological cancers. The company is focusing on the development of the lead product candidate melflufen, a first-in-class peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being tested in four clinical trials including the pivotal Phase 2 HORIZON trial and the ongoing Phase 3 OCEAN trial. Oncopeptides’ headquarters is in Stockholm, Sweden, and the company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.